PedAM
Pediatric Disease Annotations & Medicines
| Disease | dementia |
| Symptom | C0002395|alzheimer disease |
| Sentences | 22 |
| PubMedID- 26214710 | There is evidence to suggest that cytostatic chemotherapy could decrease dementia in alzheimer disease and multiple myeloma, supporting the use of cell cycle inhibitors in the therapy of degenerative diseases. |
| PubMedID- 21343896 | Wmls are described to contribute to dementia in alzheimer disease, and emerging but inconclusive evidence indicates similar effects in pd. |
| PubMedID- 23583001 | Objective: to examine effects of individual thematically-based reminiscence sessions based on the solcos model for older adults with dementia because of alzheimer disease (ad) as a pilot study. |
| PubMedID- 25707033 | dementia, including alzheimer disease, refers to cognitive disorders presenting memory impairment, difficulty in language, organizational ability, abstract thinking, object recognition, and disturbance of executive function 1. |
| PubMedID- 23604006 | Oa was administered to bvftd patients, normal controls, and a dementia control group with alzheimer disease (ad). |
| PubMedID- 22474609 | Neuropsychological assessment has featured prominently over the past 30 years in the characterization of dementia associated with alzheimer disease (ad). |
| PubMedID- 21986341 | Cordial: cognitive rehabilitation and cognitive-behavioral treatment for early dementia in alzheimer disease: a multicenter, randomized, controlled trial. |
| PubMedID- 21403020 | Results: during follow-up, 462 persons developed alzheimer disease (20 with dementia solely due to another condition were excluded). |
| PubMedID- 22984010 | These results suggest a "double hit" toward developing dementia when someone with incipient alzheimer disease also has high cardiovascular risk. |
| PubMedID- 23400708 | Apoe4 is a major genetic risk factor for alzheimer disease and is associated with dementia in down syndrome and poor neurological outcome after traumatic brain injury, cerebral hemorrhage, and other neuropathological disorders. |
| PubMedID- 24614269 | Accordingly, our aim was to compare personality changes in argentinean patients with alzheimer disease, behavioral variant of frontotemporal dementia, and primary progressive aphasia. |
| PubMedID- 20220583 | Syndromic association of behavioral and psychological symptoms of dementia in alzheimer disease and patient classification. |
| PubMedID- 24601095 | Daily life disability associated with dementia including alzheimer disease involves a series of difficulties in performing daily tasks. |
| PubMedID- 23167069 | Differential diagnosis between alzheimer disease and other causes of dementia remains important because there are differences in natural course and treatment. |
| PubMedID- 20675878 | Comprehensive examination is required to make an accurate and effective diagnosis of dementia associated with alzheimer disease. |
| PubMedID- 20361198 | Tdp-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic alzheimer disease. |
| PubMedID- 22308260 | Neurodegenerative dementia, including alzheimer disease (ad) and frontotemporal lobar degeneration (ftld), is one of the main target areas for research in biological psychiatry. |
| PubMedID- 23035075 | We sought to determine whether gba influences risk of dementia with lbdncs, alzheimer disease (ad) neuropathologic changes (adncs), or both. |
| PubMedID- 21617520 | Apolipoprotein e polymorphism and behavioral and psychological symptoms of dementia in patients with alzheimer disease. |
| PubMedID- 26386521 | Conclusion: most active drivers at the time of diagnosis of dementia are men with alzheimer disease at an early stage. |
| PubMedID- 23764686 | Effects of ramelteon on refractory behavioral and psychological symptoms of dementia in alzheimer disease. |
| PubMedID- 23407718 | Patients: autopsied subjects were classified into 5 categories: dementia with high-level alzheimer disease (ad) neuropathologic changes (ncs) but without lewy body disease (lbd) ncs (ad group; n=244), dementia with lbdncs and high-level adncs (lbd-ad group; n=224), dementia with lbdncs and no or low levels of adncs (pure dlb pdlb group; n=91), parkinson disease dementia (pdd) with no or low levels of adncs (n=81), and control group (n=269). |
Page: 1